Skip to main content
. 2022 Sep 16;21(12):1747–1756. doi: 10.1158/1535-7163.MCT-21-0875

Figure 6.

Figure 6. Head-to-head studies with the Nectin-4 ADC. A and B, Dose response to ADC in NSCLC CDX (NCI-H292) with high dose showing slower tumor regression than with BT8009; C, Response in TNBC CDX (MDA-MB-468) showing slower response to treatment with ADC; D, Equivalent regression rate with ADC, but tumor growth resumed on cessation of dosing, indicating incomplete regression in a lung PDX (LU-01–0412), unlike after BT8009; E, Lack of effect of ADC in head and neck PDX (HN-13–001) compared with BT8009 efficacy. ADC was dosed at 5 mg/kg on D0 and D7, then increased to 10 mg/kg on D14. ADC-treated tumors remain responsive to BT8009. Tumor volumes are shown as mean ± standard error of the mean (n = 3–16) and statistical analysis performed with ordinary one-way ANOVA with Tukey's post hoc test for multiple comparisons n.s., non-significant; *, P < 0.05; ***, P < 0.001; and ****, P < 0.0001.

Head-to-head studies with the Nectin-4 ADC. A and B, Dose response to ADC in NSCLC CDX (NCI-H292) with high dose showing slower tumor regression than with BT8009; C, Response in TNBC CDX (MDA-MB-468) showing slower response to treatment with ADC; D, Equivalent regression rate with ADC, but tumor growth resumed on cessation of dosing, indicating incomplete regression in a lung PDX (LU-01–0412), unlike after BT8009; E, Lack of effect of ADC in head and neck PDX (HN-13–001) compared with BT8009 efficacy. ADC was dosed at 5 mg/kg on D0 and D7, then increased to 10 mg/kg on D14. ADC-treated tumors remain responsive to BT8009. Tumor volumes are shown as mean ± standard error of the mean (n = 3–16) and statistical analysis performed with ordinary one-way ANOVA with Tukey's post hoc test for multiple comparisons n.s., non-significant; *, P < 0.05; ***, P < 0.001; and ****, P < 0.0001.